Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Jan. 3 '26)

Image
By G.M.

 


    BMC Pediatr

  1. CHEN Y, Wang Y, Tao X, Zhou M, et al
    Pediatric necrotizing pneumonia caused by mixed infection with influenza A virus and Panton-Valentine Leucocidin-producing Staphylococcus aureus: case report and literature review.
    BMC Pediatr. 2025 Dec 24. doi: 10.1186/s12887-025-06410.
    PubMed         Abstract available


    Eur J Epidemiol

  2. OSTERGREN OM, Counil E, Karimi A, Fall T, et al
    Who got tested and who got sick? Sociodemographic inequalities in COVID-19 testing and hospitalization among 1.48 million individuals in Sweden.
    Eur J Epidemiol. 2025;40:1431-1439.
    PubMed         Abstract available


    J Immunol

  3. ABE K, Holmes TH, Nguyen TT, Kim-Schulze S, et al
    Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study.
    J Immunol. 2025;214:3310-3320.
    PubMed         Abstract available

  4. OSUAGWU AE, Payne M, Bosch J, Mbonye U, et al
    Non-neutralizing antibodies against SARS-CoV-2 nucleocapsid protein mediate variant transcendent antibody-dependent cellular cytotoxicity.
    J Immunol. 2025;214:3385-3398.
    PubMed         Abstract available

  5. CHEN Y, Szelinski F, Ferreira-Gomes M, Durek P, et al
    Distinct expression of CD56 and CD19 marks molecular and functional endotypes of tetanus- versus RBD-specific human bone marrow plasma cells.
    J Immunol. 2025;214:3453-3464.
    PubMed         Abstract available


    J Infect Dis

  6. BOARDMAN SA, Hetherington C, Hughes T, Cook C, et al
    Viral Infection and the Blood-Brain Barrier: Molecular Research Insights and Therapies.
    J Infect Dis. 2025 Sep 29:jiaf455. doi: 10.1093.
    PubMed         Abstract available

  7. MOORE CM, Secor EA, Everman JL, Fairbanks-Mahnke A, et al
    The Common Cold Is Associated With Protection From SARS-CoV-2 Infections.
    J Infect Dis. 2025;232:e920-e930.
    PubMed         Abstract available

  8. JONES JM, Grebe E, Lartey I, Stone M, et al
    Estimated US Trends in SARS-CoV-2 Spike Antibody Concentrations and Correlation to Risk of First-Time Infections Based on Blood Donations, 2022.
    J Infect Dis. 2025;232:1302-1308.
    PubMed         Abstract available

  9. VERBRUGGHE C, Abdelnabi R, Maes T, Coelmont L, et al
    Functional Humoral Response During Intranasal Convalescent Plasma Prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2.
    J Infect Dis. 2025;232:1292-1301.
    PubMed         Abstract available

  10. LELAND SB, Zambrano LD, Staffa SJ, McNamara ER, et al
    Assessing Clinical Improvement of Infants Hospitalized for Respiratory Syncytial Virus-Related Critical Illness.
    J Infect Dis. 2025;232:1283-1291.
    PubMed         Abstract available


    J Virol

  11. MUTHURAMAN K, Jackman M, Liang Y, Garrett ME, et al
    Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions.
    J Virol. 2025 Nov 12:e0152325. doi: 10.1128/jvi.01523.
    PubMed         Abstract available

  12. YUAN S, Wang J, Sang X, Xie Y, et al
    Structure-guided discovery of a small molecule inhibitor of SARS-CoV-2 main protease with potent in vitro and in vivo antiviral activities.
    J Virol. 2025 Nov 14:e0100125. doi: 10.1128/jvi.01001.
    PubMed         Abstract available

  13. JIN Q, Liu R, Wang W, Xie J, et al
    Increased pathogenicity and transmission of SARS-CoV-2 Omicron XBB.1.9 subvariants, including HK.3 and EG.5.1, relative to BA.2.
    J Virol. 2025 Nov 18:e0134225. doi: 10.1128/jvi.01342.
    PubMed         Abstract available

  14. ZHANG M, Qin L, Guo R, Li J, et al
    A novel bispecific nanobody protects mice against RSV infection via intranasal administration.
    J Virol. 2025;99:e0128525.
    PubMed         Abstract available

  15. KUSAKARI D, Kishimoto N, Oshiro K, Udeda Y, et al
    Targeting envelope lipids with 2,6?di?O?methyl?3?acetyl?beta?cyclodextrin impairs infectivity of SARS?CoV?2 and Japanese encephalitis virus.
    J Virol. 2025 Dec 4:e0135725. doi: 10.1128/jvi.01357.
    PubMed         Abstract available

  16. AHMETAJ-SHALA B, Peacock TP, Baillon L, Swann OC, et al
    Resistance of endothelial cells to SARS-CoV-2 infection in vitro.
    J Virol. 2025 Dec 5:e0120525. doi: 10.1128/jvi.01205.
    PubMed         Abstract available

  17. SCHMIERER J, Lutz M, Takimoto T
    Enhanced genome replication activity of pandemic H1N1 influenza A virus through PA mutations.
    J Virol. 2025 Dec 23:e0139125. doi: 10.1128/jvi.01391.
    PubMed         Abstract available

  18. DIEGO JG-B, Arranz-Herrero J, Laghlali G, Burgess E, et al
    Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice.
    J Virol. 2025 Dec 29:e0177425. doi: 10.1128/jvi.01774.
    PubMed         Abstract available

  19. ZHAO Y, Ma Q, Jiao C, Liu J, et al
    Recombinant duck enteritis virus harboring the hemagglutinin genes of influenza virus rapidly induces specific cellular immunity in ducks.
    J Virol. 2025 Dec 30:e0201425. doi: 10.1128/jvi.02014.
    PubMed         Abstract available


    Pediatrics

  20. MESSIAH SE, Guo Y, Xie L, Ernest DK, et al
    Obesity and Severe Obesity in Youth Before and During COVID-19.
    Pediatrics. 2026;157:e2024070370.
    PubMed         Abstract available

  21. MACCALLUM-BRIDGES CL, Admon LK, Patrick SW, Kozhimannil KB, et al
    Continuous Medicaid Eligibility, Child Insurance, and Health Care Use.
    Pediatrics. 2026;157:e2025072529.
    PubMed         Abstract available


    PLoS Comput Biol

  22. SOMSEN ED, Septer KM, Field CJ, Patel DR, et al
    Quantifying viral pandemic potential from experimental transmission studies.
    PLoS Comput Biol. 2025;21:e1013808.
    PubMed         Abstract available


    PLoS One

  23. CHEN Q, Gu Y, Liu S, Li X, et al
    Single-cell alternative polyadenylation analysis reveals mechanistic insights of COVID-19-associated neurological and psychiatric effects.
    PLoS One. 2025;20:e0324689.
    PubMed         Abstract available

  24. PIENKOS S, Moore AR, Roque J, Jensen A, et al
    Drivers of prognosis and clinical trajectories differ between COVID and non-COVID acute hypoxic respiratory failure.
    PLoS One. 2025;20:e0339604.
    PubMed         Abstract available

  25. BUKHARBAYEVA A, Davis A, Rosenthal SL, Myrkassymova A, et al
    Factors associated with perceived weight gain among the adult population of Kazakhstan during the COVID-19 pandemic.
    PLoS One. 2025;20:e0339619.
    PubMed         Abstract available

  26. MISHIO BAWA E, Amoatika DA, Miller MC, Olatosi BA, et al
    Mapping the mortality-to-incidence ratios of Alzheimer's Disease and Related Dementias (ADRDs): Evidence from the South Carolina Alzheimer's disease registry.
    PLoS One. 2025;20:e0339785.
    PubMed         Abstract available

  27. DESLIPPE AL, Lavoie KL, Bacon SL, Cohen TR, et al
    How sex impacted associations between psychological distress and worry on adults' health behaviours during SARS-CoV-2.
    PLoS One. 2025;20:e0339274.
    PubMed         Abstract available

  28. JIE-YING Z, Jun L, Xue-Ya W, Rui-Xue F, et al
    The practice of drug emergency supply in China during the COVID-19 pandemic: A policy mix perspective.
    PLoS One. 2025;20:e0337700.
    PubMed         Abstract available

  29. ABBAS U, Masood KI, Iqbal T, Jamil B, et al
    Individuals with latent tuberculosis in a high TB endemic country show mild COVID-19.
    PLoS One. 2025;20:e0339240.
    PubMed         Abstract available

  30. PARK J, Nam HK, Cho SI
    Domain-specific physical activity and depressive symptoms in Korean adults: An isotemporal substitution study using KNHANES data.
    PLoS One. 2025;20.
    PubMed         Abstract available

  31. MURPHY IC, Bryan K, Burk M, Jiang R, et al
    How much is too much? A medication use evaluation of VA ICU sedation practice during the COVID-19 pandemic.
    PLoS One. 2025;20:e0340225.
    PubMed         Abstract available

  32. CHEN W, Zhu S, Shao K, Liang K, et al
    Research on the relationship between work-family conflict and burnout among civil aviation pilots after the COVID-19 pandemic.
    PLoS One. 2026;21:e0340375.
    PubMed         Abstract available

  33. MARTORELI JUNIOR JF, O Pedroso A, Lima LDES, P Gusmao CM, et al
    Prevalence and associated factors with long COVID in the Brazilian population: The role of health-related behaviors and sociodemographic characteristics.
    PLoS One. 2026;21:e0339612.
    PubMed         Abstract available

  34. AZIZ K, Ismail MS, Bibars M, Selim N, et al
    Attitude, self-efficacy, and perceived risk toward seasonal influenza vaccination among primary care physicians in Qatar: A cross-sectional study.
    PLoS One. 2026;21:e0323518.
    PubMed         Abstract available

  35. NIU X, Burkemper B, Jiang X
    Trends in self-reported dilated eye examinations among diabetic adults in California from 2011 to 2021.
    PLoS One. 2025;20:e0336246.
    PubMed         Abstract available

  36. DIAS ALB, Nascimento JR, Brito-Sousa JD, Sartim MA, et al
    Is glucose-6-phosphate dehydrogenase deficiency associated with COVID-19 infection, severity, and death? A cohort study from the Brazilian Amazon.
    PLoS One. 2025;20:e0331729.
    PubMed         Abstract available

  37. EBUNOLUWA OB, Bello AJ, Ayorinde RO, Onyejepu N, et al
    Green synthesized silver nanoparticles from Moringa: Potential for preventative treatment of SARS-CoV-2 contaminated water.
    PLoS One. 2025;20:e0338800.
    PubMed         Abstract available

  38. REINDERS FOLMER CP, Kuiper ME, van Rooij B
    The People versus Behavioral Science: Alignment between lay and scientific understanding of compliance.
    PLoS One. 2026;21:e0338675.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  39. NIELSEN BF, Park SW, Howerton E, Lorentzen OF, et al
    Complex multiannual cycles of Mycoplasma pneumoniae: Persistence and the role of stochasticity.
    Proc Natl Acad Sci U S A. 2025;122:e2509184122.
    PubMed         Abstract available

  40. XING Q, Lu L, Wang L, Chen F, et al
    Country-specific progress toward the Sustainable Development Goals: Past, present, and prospects.
    Proc Natl Acad Sci U S A. 2025;122:e2524299122.
    PubMed         Abstract available

  41. RIVERA-CARDONA J, Mahajan T, Thayer EA, Kakuturu NR, et al
    Intrinsic OASL expression governs heterogeneity in interferon induction during influenza A virus infection.
    Proc Natl Acad Sci U S A. 2026;123:e2509560123.
    PubMed         Abstract available

  42. PARK SW, Nielsen BF, Howerton E, Grenfell BT, et al
    Susceptible host dynamics explain pathogen resilience to perturbations.
    Proc Natl Acad Sci U S A. 2026;123:e2517518122.
    PubMed         Abstract available

  43. WIATR M, Wang Z, Canis M, Hernandez B, et al
    Memory B cell development in response to mRNA SARS-CoV-2 and nanoparticle immunization in mice.
    Proc Natl Acad Sci U S A. 2026;123:e2527869123.
    PubMed         Abstract available

  44. ARNING N, Fryer HR, Wilson DJ
    Identifying direct risk factors in UK Biobank via simultaneous Bayesian-frequentist model-averaged hypothesis testing using Doublethink.
    Proc Natl Acad Sci U S A. 2026;123:e2514138122.
    PubMed         Abstract available


    Vaccine

  45. JIANG J, Lam KF, Lau EHY, Yin G, et al
    Learning from the omicron BA.4/5 dominance: Strategies for future vaccination preparedness.
    Vaccine. 2025;71:128058.
    PubMed         Abstract available

  46. TOWACHIRAPORN S, Thongwitokomarn H, Salee P
    The association between COVID-19 vaccination with the prevalence of post-COVID conditions in Thai patients with mild COVID-19.
    Vaccine. 2025;71:128060.
    PubMed         Abstract available

  47. BUDD EL, De Anda S, Chaovalit P, Vu AH, et al
    Psychometric testing of two measures of vaccination attitudes among U.S. Latine respondents.
    Vaccine. 2025;71:128044.
    PubMed         Abstract available

  48. NOWZARI F, Nowzari F, Kian M, Zahedi M, et al
    Evolution and trends in non-viral mRNA Cancer vaccines: A scoping review from 2015 to 2025.
    Vaccine. 2025;71:128059.
    PubMed         Abstract available

  49. BJORK J, Dietler D, Bonander C, Moghaddassi M, et al
    Vaccine protection against COVID-19 mortality in relation to time since last booster dose among nursing home residents in Sweden - A case-control study over 35 months.
    Vaccine. 2025;71:128043.
    PubMed         Abstract available

  50. NKEREUWEM O, Jallow AO, Jallow DN, Owolabi J, et al
    Acceptance of a newly introduced COVID-19 vaccine among pregnant women and their decision influencers: a qualitative study in The Gambia.
    Vaccine. 2025;71:128070.
    PubMed         Abstract available

  51. NOGUCHI S, Ishimaru T, Yatera K, Machida M, et al
    Factors associated with respiratory syncytial virus vaccination among Japanese adults aged 60 years and older: an internet-based cross-sectional study.
    Vaccine. 2025;71:128114.
    PubMed         Abstract available


    Virology

  52. MILEWSKA A, Konkel R, Hoffmann M, Pohlmann S, et al
    Spumigins produced by Nodularia spumigena are natural serine protease inhibitors with anti-SARS-CoV-2 activity.
    Virology. 2026;615:110763.
    PubMed         Abstract available

  53. TERVO S, Zalewski A, Vauhkonen H, Nieoczym M, et al
    Virus circulation in native, introduced, and farmed mustelids in Poland.
    Virology. 2026;615:110771.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »